230 related articles for article (PubMed ID: 34139918)
1. Multidimensional mechanisms of metformin in cancer treatment.
Singh-Makkar S; Pandav K; Hathaway D; Paul T; Youssef P
Tumori; 2022 Apr; 108(2):111-118. PubMed ID: 34139918
[TBL] [Abstract][Full Text] [Related]
2. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena.
Martin-Castillo B; Vazquez-Martin A; Oliveras-Ferraros C; Menendez JA
Cell Cycle; 2010 Mar; 9(6):1057-64. PubMed ID: 20305377
[TBL] [Abstract][Full Text] [Related]
3. Metformin and cancer.
Vallianou NG; Evangelopoulos A; Kazazis C
Rev Diabet Stud; 2013; 10(4):228-35. PubMed ID: 24841876
[TBL] [Abstract][Full Text] [Related]
4. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
5. Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review.
Ahmed ZSO; Golovoy M; Abdullah Y; Ahmed RSI; Dou QP
Recent Pat Anticancer Drug Discov; 2021; 16(2):161-186. PubMed ID: 34132186
[TBL] [Abstract][Full Text] [Related]
6. Metformin: Insights into its anticancer potential with special reference to AMPK dependent and independent pathways.
Ikhlas S; Ahmad M
Life Sci; 2017 Sep; 185():53-62. PubMed ID: 28755883
[TBL] [Abstract][Full Text] [Related]
7. Metformin exhibits antineoplastic effects on Pten-deficient endometrial cancer by interfering with TGF-β and p38/ERK MAPK signalling.
Ruiz-Mitjana A; Vidal-Sabanés M; Navaridas R; Perramon-Güell A; Yeramian A; Nicholson-Sabaté N; Egea J; Encinas M; Matias-Guiu X; Dolcet X
Biomed Pharmacother; 2023 Dec; 168():115817. PubMed ID: 37925934
[TBL] [Abstract][Full Text] [Related]
8. Metformin and Breast Cancer: Molecular Targets.
Faria J; Negalha G; Azevedo A; Martel F
J Mammary Gland Biol Neoplasia; 2019 Jun; 24(2):111-123. PubMed ID: 30903363
[TBL] [Abstract][Full Text] [Related]
9. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
10. Metformin: multi-faceted protection against cancer.
Del Barco S; Vazquez-Martin A; Cufí S; Oliveras-Ferraros C; Bosch-Barrera J; Joven J; Martin-Castillo B; Menendez JA
Oncotarget; 2011 Dec; 2(12):896-917. PubMed ID: 22203527
[TBL] [Abstract][Full Text] [Related]
11. Metabolic roles of AMPK and metformin in cancer cells.
Choi YK; Park KG
Mol Cells; 2013 Oct; 36(4):279-87. PubMed ID: 23794020
[TBL] [Abstract][Full Text] [Related]
12. DEPTOR-related mTOR suppression is involved in metformin's anti-cancer action in human liver cancer cells.
Obara A; Fujita Y; Abudukadier A; Fukushima T; Oguri Y; Ogura M; Harashima S; Hosokawa M; Inagaki N
Biochem Biophys Res Commun; 2015 May; 460(4):1047-52. PubMed ID: 25843797
[TBL] [Abstract][Full Text] [Related]
13. Crucial microRNAs and genes in metformin's anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis.
Li Y; Li L; Zhang G; Wang Y; Chen H; Kong R; Pan S; Sun B
Invest New Drugs; 2018 Feb; 36(1):20-27. PubMed ID: 28875433
[TBL] [Abstract][Full Text] [Related]
14. Metformin: taking away the candy for cancer?
Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
[TBL] [Abstract][Full Text] [Related]
15. The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development.
Gong J; Kelekar G; Shen J; Shen J; Kaur S; Mita M
Target Oncol; 2016 Aug; 11(4):447-67. PubMed ID: 26864078
[TBL] [Abstract][Full Text] [Related]
16. Molecular targets of metformin antitumor action.
Sośnicki S; Kapral M; Węglarz L
Pharmacol Rep; 2016 Oct; 68(5):918-25. PubMed ID: 27362768
[TBL] [Abstract][Full Text] [Related]
17. Metformin - its potential anti-cancer and anti-aging effects.
Podhorecka M; Ibanez B; Dmoszyńska A
Postepy Hig Med Dosw (Online); 2017 Mar; 71(0):170-175. PubMed ID: 28258677
[TBL] [Abstract][Full Text] [Related]
18. Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.
Guo Q; Liu Z; Jiang L; Liu M; Ma J; Yang C; Han L; Nan K; Liang X
Mol Med Rep; 2016 Mar; 13(3):2590-6. PubMed ID: 26847819
[TBL] [Abstract][Full Text] [Related]
19. Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications.
Bashraheel SS; Kheraldine H; Khalaf S; Moustafa AA
Biomed Pharmacother; 2023 Jun; 162():114676. PubMed ID: 37037091
[TBL] [Abstract][Full Text] [Related]
20. Metformin in Esophageal Carcinoma: Exploring Molecular Mechanisms and Therapeutic Insights.
Papadakos SP; Argyrou A; Lekakis V; Arvanitakis K; Kalisperati P; Stergiou IE; Konstantinidis I; Schizas D; Koufakis T; Germanidis G; Theocharis S
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
